ClinicalTrials.Veeva

Menu

Optical Imaging Scans for the Diagnosis of Skin Cancer in Patients With Lesions

Emory University logo

Emory University

Status

Not yet enrolling

Conditions

Skin Disorder
Skin Neoplasm
Malignant Skin Neoplasm

Treatments

Procedure: Quantitative Oblique Back-Illumination Microscopy
Radiation: Radiation Therapy

Study type

Interventional

Funder types

Other
NIH

Identifiers

NCT07213154
P30CA138292 (U.S. NIH Grant/Contract)
WINSHIP6407-24 (Other Identifier)
STUDY00008502 (Other Identifier)
NCI-2025-02356 (Registry Identifier)

Details and patient eligibility

About

This clinical trial studies how well an optical imaging scan called quantitative oblique back-illumination microscopy (qOBM) helps in diagnosing skin cancer in patients with skin lesions. qOBM is a non-invasive procedure that uses red light for illumination, and may work better than no imaging procedures in aiding doctors in diagnosing skin lesions.

Full description

PRIMARY OBJECTIVE:

I. To perform a first-in-human study to assess the ability of a qOBM handheld device to reliably image skin pathology in-situ and in-vivo.

SECONDARY OBJECTIVES:

I. Characterize a wide variety of lesions including but limited to:

Ia. Malignant lesions: basal cell cancers, squamous cell cancers, Merkel cell cancer, melanoma, etc,; Ib. Non-malignant lesions: keloids, surgical scars, actinic keratosis, benign and dysplastic nevi, cysts, lipoma; Ic. Inflammatory conditions: psoriasis, eczema, alopecia, acne, wounds, etc); Id. Characterize pre and post treatment changes in the lesion as well as the surrounding normal tissue stroma (examples, but not limited to: changes to hair follicles, epidermis, dermis, subcutaneous tissue, erector pillae muscles, vessels, nerves, etc); Ie. Correlate optical findings with histological findings for lesions that would have been removed surgically and/or are biopsied (examples, but not limited to: removal of a skin cancer where optical imaging is used to characterize peripheral extent of the lesion as well as depth of penetration, a benign versus malignant lesion, pigmented versus [vs] non-pigmented lesion, etc).

OUTLINE: Patients are assigned to 1 of 2 groups.

GROUP I: Patients who have skin melanoma and/or suspected dysplastic nevi undergo qOBM optical imaging scan on study. Patients may undergo 2 additional qOBM optical imaging scans at the discretion of the treating physician. After qOBM scans, patients who are diagnosed with skin cancer may proceed to Group II.

GROUP II: Patients with skin cancer who are undergoing standard of care (SOC) radiation therapy (RT) undergo qOBM optical imaging scans prior to- and during or after SOC RT on study. Patients may also undergo qOBM optical imaging scans additional at approximately 1, 6, and 12 months after completion of SOC RT at the discretion of the treating physician.

Enrollment

10 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Male or Female
  • Candidate with skin lesions
  • Signed study-specific informed consent prior to study entry
  • ≥ 18 years old

Exclusion criteria

  • Prior surgery or radiotherapy to the area to be treated

Trial design

Primary purpose

Diagnostic

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

10 participants in 2 patient groups

Group I (qOBM)
Experimental group
Description:
Patients who have skin melanoma and/or suspected dysplastic nevi undergo qOBM optical imaging scan on study. Patients may undergo 2 additional qOBM optical imaging scans at the discretion of the treating physician. After qOBM scans, patients who are diagnosed with skin cancer may proceed to Group II.
Treatment:
Procedure: Quantitative Oblique Back-Illumination Microscopy
Group II (qOBM, SOC RT)
Experimental group
Description:
GROUP II: Patients with skin cancer who are undergoing SOC RT undergo qOBM optical imaging scans prior to- and during or after SOC RT on study. Patients may also undergo qOBM optical imaging scans additional at approximately 1, 6, and 12 months after completion of SOC RT at the discretion of the treating physician.
Treatment:
Radiation: Radiation Therapy
Procedure: Quantitative Oblique Back-Illumination Microscopy

Trial contacts and locations

2

Loading...

Central trial contact

Mohammad K. Khan, MD, PhD, MS, FACRO, FACR, DABR

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems